標(biāo)題：Research Grade Risankizumab利散吉珠單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/6180.html

名稱：Research Grade Risankizumab利散吉珠單抗

別名：Risankizumab利散吉珠單抗，BI 655066, risankizumab-rzaa

CAS: 1612838-76-2

貨號(hào)：DHJ63101

適用物種：Human

寄主物種：Humanized

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG1, kappa

應(yīng)用：Research Grade Biosimilar

UniProt：Q9NPF7

靶點(diǎn)：SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19

用途范圍：僅用于科研

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Risankizumab. PMID: 37216077

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. PMID: 35644154

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. PMID: 35644155

Risankizumab for the treatment of psoriasis. PMID: 31460804

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. PMID: 28423301

Risankizumab for the treatment of active psoriatic arthritis in adults. PMID: 37772959

Risankizumab: First Global Approval. PMID: 31098898

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. PMID: 34911706

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). PMID: 37488811

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. PMID: 35996400

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. PMID: 30097359

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. PMID: 32594522

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. PMID: 31280967

Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease. PMID: 36214282

Risankizumab in moderate-to-severe plaque psoriasis. PMID: 31578912

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. PMID: 36282537

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. PMID: 34652810

Risankizumab improves PsA. PMID: 35082372

Risankizumab in the treatment of psoriasis - literature review. PMID: 31462831

Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data. PMID: 38095092

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. PMID: 32632826

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. PMID: 32267471

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. PMID: 36282530

Risankizumab for psoriasis. PMID: 30097360

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. PMID: 34815219

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. PMID: 30518998

Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). PMID: 36321844

The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-alpha Inadequate Response Mechanisms. PMID: 36515243

Risankizumab for the treatment of moderate to severe psoriasis. PMID: 30462554

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. PMID: 37553030

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease. PMID: 37368103

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. PMID: 35603992

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. PMID: 37745273

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. PMID: 36200762

Risankizumab (Skyrizi): CADTH Reimbursement Review: Therapeutic area: Crohn disease. PMID: 37934852

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. PMID: 32427307

Update on risankizumab for the treatment of moderate to severe psoriasis. PMID: 32933320

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. PMID: 31583255

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience. PMID: 37077769

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. PMID: 28411872

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. PMID: 31758502